| 1 | Global burden and drivers of hyperglycemia:Estimates and predictions from 1990 to 2050显示文摘Hyperglycemia is a key risk factor for death and disability worldwide.To better inform prevention strategies,we aimed to delineate and predict the temporal,spatial,and demographic patterns in mean fasting plasma glucose(FPG)levels and their related disease burden globally.Based on the Global Burden of Disease Study 2019,we estimated the distributions of mean FPG levels and high FPG-related disease burden by age,sex,year,socioeconomic status(SES),and geographical region from 1990 to 2050. | Hui-Ling Qiu Shujun Fan Kaixin Zhou Zhini He Matthew H.E.M.Browning Luke D.Knibbs Tianyu Zhao Ya-Na Luo Xiao-Xuan Liu Li-Xin Hu Jia-Xin Li Yi-Dan Zhang Yu-Ting Xie Joachim Heinrich Guang-Hui Dong Bo-Yi Yang | 2023 | The Innovation2023，4，4： | 0 |
| 3 | Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines显示文摘Monoamine neurotransmitters such as serotonin and dopamine are loaded by vesicular monoamine transporter 2(VMAT2)into synaptic vesicles for storage and subsequent release in neurons.Impaired VMAT2 function underlies various neuropsychiatric diseases.VMAT2 inhibitors reserpine and tetrabenazine are used to treat hypertension,movement disorders associated with Huntington’s Disease and Tardive Dyskinesia.Despite its physiological and pharmacological significance,the structural basis underlying VMAT2 substrate recognition and its inhibition by various inhibitors remains unknown.Here we present cryo-EM structures of human apo VMAT2 in addition to states bound to serotonin,tetrabenazine,and reserpine.These structures collectively capture three states,namely the lumen-facing,occluded,and cytosol-facing conformations.Notably,tetrabenazine induces a substantial rearrangement of TM2 and TM7,extending beyond the typical rocker-switch movement.These functionally dynamic snapshots,complemented by biochemical analysis,unveil the essential components responsible for ligand recognition,elucidate the proton-driven exchange cycle,and provide a framework to design improved pharmaceutics targeting VMAT2. | Yuwei Wang Pei Zhang Yulin Chao Zhini Zhu Chuanhui Yang Zixuan Zhou Yaohui Li Yonghui Long Yuehua Liu Dianfan Li Sheng Wang Qianhui Qu | 2024 | Cell Research2024，34，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员